Ovid Therapeutics to Present at Upcoming August Investor Conferences
NEW YORK, July 30, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to meaningfully improving the lives of people affected by certain epilepsies and brain conditions, today announced that management will participate in two upcoming investor conferences in August:
- BTIG Virtual Biotechnology Conference – Ovid will participate in a fireside chat on Tuesday, August 6th at 10:00 a.m. ET.
- 2024 Wedbush PacGrow Healthcare Conference – Ovid will participate in a panel discussion on Tuesday, August 13th at 10:15 a.m. ET.
Live webcasts of the fireside chat and panel discussion can be accessed through the Events & Presentations section of the Company’s website at . An archived replay of the webcast will be available on the Company’s website following the live presentation.
About Ovid Therapeutics
Ovid Therapeutics Inc. is a New York-based biopharmaceutical company that is dedicated to improving the lives of people affected by certain epilepsies and brain conditions with seizure symptoms. The Company is advancing a pipeline of novel, targeted small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of seizures and other neurological symptoms. Ovid is developing: OV888/GV101 capsule, a potent and highly selective ROCK2 inhibitor capsule, for the potential treatment of cerebral cavernous malformations and other rare central nervous system diseases; OV329, a GABA-aminotransferase inhibitor, a potential therapy for treatment-resistant seizures; and OV350, a direct activator of the KCC2 transporter, for the potential treatment of epilepsies and other psychiatric conditions. For more information about these and other Ovid research programs, please visit .
Contacts
Investor Relations:
Garret Bonney
617-735-6093
